



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Barbara K. Finck et al.

Docket No.: 2945-A

Serial No: 09/602,351

Group Art Unit: 1647

Filed: June 23, 2000

Examiner: David S. Romeo

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF
MEDICAL DISORDERS

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 30 2002

AMENDMENT AND RESPONSE TO OFFICE ACTION

TECH CENTER 1600/2900

In response to the Office Action issued April 22, 2002 in the above-captioned application, the applicants request that the application be amended as follows:

In the claims:

1. (Amended) A method of treating psoriasis in a human patient having psoriasis comprising administering to said patient a therapeutically effective amount of TNFR:Fc.

Please cancel claim 2.

3. (Amended) The method of claim 1, wherein said TNFR:Fc is administered in an amount and for a time sufficient to induce an improvement over baseline in an indicator selected from the group consisting of psoriasis area and severity index (PASI) and Target Lesion Assessment Score, wherein said baseline is the value established for said indicator in said patient by examining the patient within 60 days of administering the first dose of TNFR:Fc.

4. (Amended) The method of Claim 1, wherein the TNFR:Fc is administered one or more times per week.

5. (Amended) The method of Claim 1, wherein the TNFR:Fc is administered by subcutaneous injection.

6. (Amended) The method of Claim 5, wherein the patient is an adult and the amount of TNFR:Fc injected is 5-12 mg/m² of body surface area, 25 mg or 50 mg.